1 / 1
CJC-1295 is a synthetic, tetrasubstituted peptide analogue of growth hormone releasing hormone (GHRH), designed to stimulate and sustain the secretion of endogenous growth hormone (GH). Unlike native GHRH, which has a short half-life, CJC-1295 incorporates a Drug Affinity Complex (DAC) technology, allowing it to bind covalently to albumin in the bloodstream and prolong its biological half-life to over 8 days. This innovation makes CJC-1295 a long-acting GHRH analogue with significant potential in anti-aging, growth deficiency, metabolic regulation, muscle-wasting disorders, and regenerative medicine.
CJC-1295 acts on the GHRH receptor located on somatotropic cells in the anterior pituitary gland. Its biological function mimics that of native GHRH, but with a significantly extended half-life due to the DAC modification. This sustained action enables stable pulsatile release of GH and increased production of insulin-like growth factor 1 (IGF-1).
By triggering the body’s own GH and IGF-1 pathways, CJC-1295 avoids many of the drawbacks associated with exogenous GH therapy, such as receptor desensitization and safety concerns.
In early-phase clinical trials, CJC-1295 has demonstrated:
Animal and human studies have shown that CJC-1295:
As GH and IGF-1 levels naturally decline with age, CJC-1295 is increasingly studied as an anti-aging intervention to:
CJC-1295 shows promise in addressing insulin resistance and metabolic syndrome by:
Our CJC-1295 API is produced using solid-phase peptide synthesis (SPPS) and purified using HPLC to achieve high purity and batch-to-batch consistency.
(HPLC confirmed)
Low residual solvents and heavy metals
Endotoxin-free, non-immunogenic synthesis route
Available in custom quantities: milligram to kilogram scale
CJC-1295 is considered one of the most promising long-acting GHRH analogues, with potential applications in:
Ongoing clinical trials are exploring its use as an alternative to recombinant GH, particularly in populations seeking safer, more physiological hormone modulation.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It works by stimulating the GHRH receptors in the anterior pituitary gland, triggering the natural production and release of endogenous growth hormone (GH) and IGF-1.
Drug Affinity Complex (DAC) technology enables CJC-1295 to bind covalently to albumin in the bloodstream. This prevents rapid enzymatic degradation and extends its biological half-life to over 8 days.
CJC-1295 supports growth hormone deficiency treatment, promotes lean muscle preservation, reduces body fat, improves sleep quality and bone density, and aids in metabolic regulation and fatigue resistance.
Unlike exogenous GH injections, CJC-1295 stimulates the body's natural pulsatile release of GH and IGF-1, helping avoid receptor desensitization and potential safety concerns linked to direct GH replacement.
The API is produced using solid-phase peptide synthesis (SPPS) and HPLC purification. It features a purity of ≥ 99%, low residual solvents and heavy metals, and an endotoxin-free synthesis route available from milligram to kilogram scales.
